NCT04997421View on ClinicalTrials.gov

Safety and Efficacy of HA380 Hemoadsorption in Patients With Septic Shock

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Septic ShockAcute Kidney Injury
Interventions
DEVICE

Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes

Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).

DEVICE

Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes

Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)

Trial Locations (1)

Unknown

RECRUITING

Turku University Hospital, Turku

All Listed Sponsors
collaborator

University of Turku

OTHER

lead

Turku University Hospital

OTHER_GOV